Zacks Investment Research upgraded shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) from a sell rating to a hold rating in a report published on Tuesday.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

A number of other equities research analysts have also commented on MCRB. BidaskClub upgraded shares of Seres Therapeutics from a hold rating to a buy rating in a report on Tuesday, July 25th. ValuEngine upgraded shares of Seres Therapeutics from a sell rating to a hold rating in a report on Tuesday, August 1st. Canaccord Genuity set a $20.00 price target on shares of Seres Therapeutics and gave the company a buy rating in a report on Thursday, August 3rd. HC Wainwright reiterated a buy rating and set a $19.00 price target (up from $15.00) on shares of Seres Therapeutics in a report on Friday, August 4th. Finally, Cantor Fitzgerald reiterated a buy rating on shares of Seres Therapeutics in a report on Wednesday, August 30th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $18.00.

Seres Therapeutics (MCRB) traded down $0.37 during trading hours on Tuesday, reaching $9.15. 179,385 shares of the company were exchanged, compared to its average volume of 211,346. Seres Therapeutics has a 52 week low of $8.85 and a 52 week high of $17.42. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.53 and a quick ratio of 6.53.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.22. Seres Therapeutics had a negative net margin of 267.15% and a negative return on equity of 82.11%. The company had revenue of $23.00 million during the quarter, compared to analyst estimates of $17.29 million. During the same period in the prior year, the business posted ($0.46) EPS. The firm’s revenue was up 76.9% compared to the same quarter last year. equities research analysts expect that Seres Therapeutics will post -2.37 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/seres-therapeutics-inc-mcrb-upgraded-to-hold-by-zacks-investment-research/1705514.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC bought a new position in Seres Therapeutics in the 3rd quarter worth $170,000. Perceptive Advisors LLC bought a new position in Seres Therapeutics in the 3rd quarter worth $2,165,000. Schwab Charles Investment Management Inc. raised its holdings in Seres Therapeutics by 12.8% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 103,286 shares of the biotechnology company’s stock worth $1,657,000 after purchasing an additional 11,743 shares in the last quarter. Schroder Investment Management Group bought a new position in Seres Therapeutics in the 3rd quarter worth $1,088,000. Finally, JPMorgan Chase & Co. raised its holdings in Seres Therapeutics by 39.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock worth $6,160,000 after purchasing an additional 106,479 shares in the last quarter. Institutional investors and hedge funds own 74.77% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.